Primaxin in the treatment of acute bacterial pneumonia in adults.

Abstract

Imipenem (N-Formimidoyl thienamycin) (MK-0787) is a new beta-lactam carbapenem antibiotic. When it is combined with the renal dipeptidase inhibitor cilastatin (MK-0791) the combination is known as primaxin. In this study 28 adult patients (24 males and 4 females) with acute bacterial pneumonia were treated with primaxin. Twenty-one patients were evaluable and 20 (95%) were clinically cured of their pneumonia. Bacteriological cures were demonstrated in 84% of the cases. One patient with a susceptible Pseudomonas aeruginosa failed. Major complications or toxic reactions included antibiotic associated diarrhoea in one patient; hypotension in one patient; increased grand mal seizures in one patient and elevated liver function studies in one patient. Results of this study suggest that primaxin will be useful in the treatment of a variety of serious Gram-positive and Gram-negative pneumonias. The true incidence of possible toxic reactions with this drug is not known at this time and awaits further experience.

• Authors: R J Gebhart, R J Duma, P M Patterson, J W Bagett, D S Williams
• Journal: The Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 15 Issue 2 Pg. 233-8 (Feb 1985) ISSN: 0305-7453 [Print] England
• PMID: 3980311 (Publication Type: Journal Article)

Chemical References

• Cyclopropanes
• Drug Combinations
• Thienamycins
• Cilastatin
• Imipenem
• Cilastatin, Imipenem Drug Combination
• Dipeptidases

Topics

• Adult
• Aged
• Cilastatin
• Cilastatin, Imipenem Drug Combination
• Cyclopropanes (adverse effects, therapeutic use)
• Dipeptidases (antagonists & inhibitors)
• Drug Combinations (adverse effects, therapeutic use)
• Drug Resistance, Microbial
• Female
• Humans
• Imipenem
• Male
• Microbial Sensitivity Tests
• Middle Aged
• Pneumonia (drug therapy, microbiology)
• Thienamycins (adverse effects, therapeutic use)